Serologic problems associated with administration of intravenous immune globulin (IVIg)

Publications

Share / Export Citation / Email / Print / Text size:

Immunohematology

American National Red Cross

Subject: Medical Laboratory Technology

GET ALERTS SUBSCRIBE

ISSN: 0894-203X
eISSN: 1930-3955

DESCRIPTION

5
Reader(s)
18
Visit(s)
0
Comment(s)
0
Share(s)

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue / page

Archive
Volume 37 (2021)
Volume 36 (2020)
Volume 35 (2019)
Volume 34 (2018)
Volume 33 (2017)
Volume 32 (2016)
Volume 31 (2015)
Volume 30 (2014)
Volume 29 (2013)
Volume 28 (2012)
Volume 27 (2011)
Volume 26 (2010)
Volume 25 (2009)
Volume 24 (2008)
Volume 23 (2007)
Volume 22 (2006)
Volume 21 (2005)
Volume 20 (2004)
Volume 19 (2003)
Volume 18 (2002)
Volume 17 (2001)
Volume 16 (2000)
Volume 15 (1999)
Volume 14 (1998)
Volume 13 (1997)
Volume 12 (1996)
Volume 11 (1995)
Volume 10 (1994)
Volume 9 (1993)
Volume 8 (1992)
Volume 7 (1991)
Volume 6 (1990)
Volume 5 (1989)
Volume 4 (1988)
Volume 3 (1987)
Related articles

VOLUME 35 , ISSUE 1 (March 2019) > List of articles

Serologic problems associated with administration of intravenous immune globulin (IVIg)

D.R. Branch *

Keywords : IVIg, ABO discrepancies, DAT, isoagglutinins, alloantibodies

Citation Information : Immunohematology. Volume 35, Issue 1, Pages 13-15, DOI: https://doi.org/10.21307/immunohematology-2020-006

License : (Transfer of Copyright)

Published Online: 15-February-2021

ARTICLE

ABSTRACT

Intravenous immune globulin (IVIg) is manufactured from large pools of donor plasma and contains a high diversity of antibodies, primarily IgG. For this reason, IVIg is routinely used as antibody replacement therapy for patients having primary immunodeficiencies. In 1981, IVIg was also found to be a strong immunomodulator of various inflammatory and autoimmune conditions. This observation has led to the exponential increase in the use of IVIg throughout the world, with the United States and Canada being the biggest users of IVIg. Although relatively rare, adverse events, such as hemolytic anemia and thrombosis, can complicate the administration of IVIg. More frequently, the administration of IVIg can cause serologic challenges for the transfusion service including ABO discrepancies, positive direct antiglobulin tests, positive antibody detection tests, and incompatible crossmatches. This article will review each of the potential transfusion service challenges associated with IVIg administration.

You don't have 'Full Text' access of this article.

Purchase Article Subscribe Journal Share